Melissa Burroughs, MD
Cardiovascular Disease · Hiram, GANPI 1437485968
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 61.9% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2024 at $27,904 and has fallen 55.1% since, to $12,523 in 2025. Among cardiovascular disease clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $275.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$37K
- Novartis$7K
- Lantheus Medical Imaging, Inc.$6K
- AstraZeneca$5K
- Alnylam Pharmaceuticals Inc.$3K
- Amgen$311
- plus $2K from 20 others
What the payments were for
- Consulting fees$16,93328%
- Speaking & faculty fees$34,54058%
- Travel & lodging$3,0435%
- Food & beverage$5,0829%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 52 | $36,912 |
| Novartis | 27 | $6,508 |
| Lantheus Medical Imaging, Inc. | 12 | $6,011 |
| AstraZeneca | 24 | $4,856 |
| Alnylam Pharmaceuticals Inc. | 2 | $2,992 |
| Amgen | 14 | $311 |
| Novo Nordisk | 14 | $261 |
| Boston Scientific | 8 | $231 |
| Boehringer Ingelheim | 11 | $192 |
| Impulse Dynamics (USA) Inc. | 1 | $178 |
| Medtronic | 1 | $163 |
| Merck | 9 | $152 |
| Pfizer | 8 | $150 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $142 |
| Bayer | 6 | $114 |
| Abbott | 5 | $103 |
| Johnson & Johnson | 4 | $70 |
| Heartflow, Inc. | 2 | $63 |
| Recor Medical Inc | 1 | $33 |
| Scpharmaceuticals Inc. | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $27 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Bridgebio Pharma, Inc. | 1 | $21 |
| Phadia US Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$59,598 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 129 | $3,237,976 |
| EliquisApixaban | 378 | $360,770 |
| CamzyosMavacamten | 43 | $354,526 |
| JardianceEmpagliflozin | 232 | $212,914 |
| OzempicSemaglutide | 89 | $91,901 |
| FarxigaDapagliflozin Propanediol | 116 | $78,856 |
| EntrestoSacubitril/Valsartan | 56 | $59,001 |
| XareltoRivaroxaban | 43 | $44,942 |
| MounjaroTirzepatide | 28 | $33,324 |
| TrulicityDulaglutide | 12 | $10,993 |
| Repatha SureclickEvolocumab | 13 | $6,934 |
| Nifedipine ErNifedipine | 230 | $5,170 |
| Rosuvastatin Calcium | 410 | $4,951 |
| Clonidine | 30 | $3,900 |
| Metoprolol Succinate | 340 | $3,522 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $150 | $3,598,747507 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $36,912 | $354,52643 claims |
| Boehringer IngelheimJardiance | $192 | $212,914232 claims |
| Novo NordiskOzempic | $261 | $91,90189 claims |
| AstraZenecaFarxiga | $4,856 | $78,856116 claims |
| NovartisEntresto | $6,508 | $59,00156 claims |
| Johnson & JohnsonXarelto | $70 | $44,94243 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.
Other cardiovascular disease in Hiram
- Narendra SinghJohns Creek$1.6M
- Hunter ChampionColumbus$1.5M
- Nicolas ChronosEatonton$912K
- Jaime BurkleGainesville$628K
- Joseph MillerAtlanta$573K
- Kashyap ChoksiThomasville$263K
- Utpal PandyaAtlanta$221K
- Randolph MartinAtlanta$177K
- Hiren ShahColumbus$166K
- Mani VannanAtlanta$157K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.